NCT06969417 Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
| NCT ID | NCT06969417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CMH Kharian Medical College |
| Condition | Herpes Zoster (HZ) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-04-10 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-04-10 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities. Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain. Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.
Eligibility Criteria
Inclusion Criteria: * Diagnosed cases of herpes zoster suffering from postherpetic neuralgia * Ages: 18 to 50 * Both male and female Exclusion Criteria: * Lack of consent * Patient already taking pain killers for post herpetic neuralgia * Patients suffering from other systemic illness
Contact & Investigator
Usman Nawaz, MBBS, Mphil, PhD Pharmacology
STUDY CHAIR
CMH Kharian Medical College
Frequently Asked Questions
Who can join the NCT06969417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Herpes Zoster (HZ). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06969417 currently recruiting?
Yes, NCT06969417 is actively recruiting participants. Contact the research team at mishy2360@gmail.com for enrollment information.
Where is the NCT06969417 trial being conducted?
This trial is being conducted at Kharan, Pakistan.
Who is sponsoring the NCT06969417 clinical trial?
NCT06969417 is sponsored by CMH Kharian Medical College. The principal investigator is Usman Nawaz, MBBS, Mphil, PhD Pharmacology at CMH Kharian Medical College. The trial plans to enroll 50 participants.